Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Artes, Burnet Institute Partner on Malaria Vaccine

By Drug Discovery Trends Editor | July 29, 2014

Artes Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).
 
The project will use exciting novel technology developed at the Burnet Institute, by Deputy-Director, Associate Prof. David Anderson and colleagues. Artes holds the international patent rights and adapted the platform to vaccine production (known as the Metavax platform).
 
Purified vaccine antigens (Pfs25 and Pfs230) will be produced as virus-like particles (VLPs, a type of nano-particle) for testing in laboratory studies. The VLPs will be taken up by immune cells to prime and prepare the immune system to fight malaria.
 
Although malaria is one of the world’s leading causes of illness and death there is currently no vaccine approved for use. More than 600,000 people die of malaria each year and it most severely affects young children and pregnant women.
 
Burnet Institute Co-Head of the Centre for Biomedical Research, Prof. James Beeson said the challenges in developing an effective malaria vaccine are substantial. 
 
“One of the challenges for malaria is how to best make vaccines in order to stimulate a strong and effective immune response and boost the immune system to fight malaria infections,” Beeson said. 
 
Artes Managing Director Dr. Michael Piontek said the strong collaboration between Burnet and Artes is a great opportunity for developing new malaria vaccines, “In this new project, Burnet and Artes will combine their expertise to develop and test a novel approach for producing malaria vaccines. We are excited about the recognition and support provided by MVI for this development work.”
 
Vaccines that interrupt the transmission of malaria aim to protect whole populations, toward the ultimate goal of malaria eradication.
 
The project will focus on strategies to produce vaccines that can block the transmission of malaria infection from mosquitoes to people, as part of a program funded by MVI. 
 
”At MVI, we think that transmission-blocking vaccines could play a significant role in the eventual eradication of malaria,” said Ashley Birkett, MVI director. “We are therefore very pleased to be involved in this project, which uses an innovative approach to expressing transmission-blocking antigens.”
 
Date: July 29, 2014
Source: Burnet Institute

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50